• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval.

作者信息

Tjioe Kellen Cristine, Miranda-Galvis Marisol, Mamouni Kenza, Freitas Thalyta, Sharara Muhannad, Santellano Brenda, Guillén-Lopez Claudia, Cortes Jorge E

机构信息

Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA.

出版信息

Blood Adv. 2025 Aug 12;9(15):3810-3813. doi: 10.1182/bloodadvances.2024014340.

DOI:10.1182/bloodadvances.2024014340
PMID:40367411
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12311582/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c678/12311582/f4a31d70251f/BLOODA_ADV-2024-014340-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c678/12311582/9746a5d57c23/BLOODA_ADV-2024-014340-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c678/12311582/f4a31d70251f/BLOODA_ADV-2024-014340-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c678/12311582/9746a5d57c23/BLOODA_ADV-2024-014340-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c678/12311582/f4a31d70251f/BLOODA_ADV-2024-014340-gr1.jpg

相似文献

1
Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval.白血病的药物研发：从首次报告到药物获批的临床试验综合分析
Blood Adv. 2025 Aug 12;9(15):3810-3813. doi: 10.1182/bloodadvances.2024014340.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Assessment of the official national insurance coverage of regenerative medical products for ophthalmic diseases in Japan following regulatory approval.日本再生医疗产品获批上市后其眼科疾病官方医保覆盖情况评估。
Regen Ther. 2025 Jul 12;30:384-388. doi: 10.1016/j.reth.2025.07.003. eCollection 2025 Dec.
4
Promoting the development and approval of new traditional Chinese medicines in China: a pooled analysis of data from 2013 to 2024.推动中国新型中药的研发与审批：2013年至2024年数据的汇总分析
Front Med (Lausanne). 2025 Jun 16;12:1559703. doi: 10.3389/fmed.2025.1559703. eCollection 2025.
5
Landscape of Post-Marketing Requirements Under the Pediatric Research Equity Act for Antibiotics from 2009-2024.2009年至2024年《儿科研究公平法案》下抗生素上市后要求的概况
Antibiotics (Basel). 2025 Jun 6;14(6):583. doi: 10.3390/antibiotics14060583.
6
The global landscape and development pipeline for childhood cancer medicines: a comprehensive analysis with dashboard generation.儿童癌症药物的全球格局与研发进展：基于仪表盘生成的综合分析
Lancet Child Adolesc Health. 2025 Aug;9(8):544-552. doi: 10.1016/S2352-4642(25)00142-7. Epub 2025 Jun 25.
7
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.急性和慢性白血病患者弥散性血管内凝血的治疗
Cochrane Database Syst Rev. 2015 Jun 24;2015(6):CD008562. doi: 10.1002/14651858.CD008562.pub3.
8
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
9
A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?美国生物类似药批准的系统评价：FDA 需要什么证据，制造商如何回应？
J Manag Care Spec Pharm. 2017 Dec;23(12):1234-1244. doi: 10.18553/jmcp.2017.23.12.1234.
10
Representation of Native Hawaiian and Pacific Islander Individuals in Clinical Trials.临床研究中对夏威夷原住民和太平洋岛民个体的代表性。
JAMA Netw Open. 2024 Oct 1;7(10):e2442204. doi: 10.1001/jamanetworkopen.2024.42204.

本文引用的文献

1
Acute myeloid leukemia: current progress and future directions.急性髓系白血病：当前进展与未来方向。
Blood Cancer J. 2021 Feb 22;11(2):41. doi: 10.1038/s41408-021-00425-3.
2
Clinical trial risk in leukemia: Biomarkers and trial design.白血病临床试验风险：生物标志物与试验设计。
Hematol Oncol. 2021 Feb;39(1):105-113. doi: 10.1002/hon.2818. Epub 2020 Oct 28.
3
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.2009-2018 年新药推向市场所需的研发投资估算。
JAMA. 2020 Mar 3;323(9):844-853. doi: 10.1001/jama.2020.1166.
4
Full publication of results initially presented in abstracts.初步以摘要形式呈现的结果的完整发表。
Cochrane Database Syst Rev. 2018 Nov 20;11(11):MR000005. doi: 10.1002/14651858.MR000005.pub4.
5
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.伊马替尼治疗慢性髓性白血病的长期疗效
N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.
6
Published abstracts at international meetings often over- or underestimate the initial response rate.
Blood. 2017 Apr 20;129(16):2326-2328. doi: 10.1182/blood-2017-01-763144. Epub 2017 Mar 6.
7
Genomic Classification and Prognosis in Acute Myeloid Leukemia.急性髓系白血病的基因组分类与预后
N Engl J Med. 2016 Jun 9;374(23):2209-2221. doi: 10.1056/NEJMoa1516192.
8
Transition from meeting abstract to full-length journal article for randomized controlled trials.随机对照试验从会议摘要到完整期刊文章的转变。
JAMA. 2006 Mar 15;295(11):1281-7. doi: 10.1001/jama.295.11.1281.
9
An observational study of orthopaedic abstracts and subsequent full-text publications.一项关于骨科摘要及后续全文出版物的观察性研究。
J Bone Joint Surg Am. 2002 Apr;84(4):615-21. doi: 10.2106/00004623-200204000-00017.
10
Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis.医疗保健中的系统评价：在荟萃分析中调查和处理发表偏倚及其他偏倚
BMJ. 2001 Jul 14;323(7304):101-5. doi: 10.1136/bmj.323.7304.101.